Compare Autodesk Inc (ADSK) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Medpace Holdings Inc — how do they compare? Autodesk Inc trades at $206.41 (market cap $44.84B), while Medpace Holdings Inc trades at $531.77 (market cap $15.60B). The key difference: Autodesk Inc is far larger — about 2.9× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | MEDP | |
|---|---|---|
Market Cap | $44.84B | $15.60B |
Sector | Technology | Technology |
52-Week High | $326.79 | $620.59 |
52-Week Low | $187.72 | $308.88 |
Enterprise Value | $44.64B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.
MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
